PDF Cover

Durvalumab Market

The market for Durvalumab was estimated at $2.4 billion in 2024; it is anticipated to increase to $4.9 billion by 2030, with projections indicating growth to around $8.8 billion by 2035.

Report ID:DS1802505
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Durvalumab
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Durvalumab Market Outlook

Revenue, 2024

$2.4B

Forecast, 2034

$7.8B

CAGR, 2025 - 2034

12.4%

The Durvalumab industry revenue is expected to be around $2.7 billion in 2025 and expected to showcase growth with 12.4% CAGR between 2025 and 2034. The continuous rise of Durvalumab in the market indicates its significance and growing relevance in today's pharmaceutical landscape. The impressive annual growth rate reflects the advancement of key factors. Notably the escalating prevalence of cancer globally mixed with increasing awareness about treatment options and significant progress in medical biotechnology is driving a consistent demand for effective therapies like Durvalumab. Moreover sizable investments in research and development and favorable regulatory measures are anticipated to boost Durvalumabs market impact, in the future.

Durvalumab is a of human made antibody mainly used in immunotherapy for treating of cancer like urothelial carcinoma and lung cancer among others It belongs to the advanced group of PD-LI inhibitors and functions by preventing the interaction between PD-LI and PD-I which helps in stopping cancer cells from hiding from the body's immune system Recent developments in cancer treatment strategies such, as personalized medicine and targeted therapies have brought Durvalumab into focus increasing its popularity .

Durvalumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Durvalumab Market Outlook

Market Key Insights

  • The Durvalumab market is projected to grow from $2.4 billion in 2024 to $7.8 billion in 2034. This represents a CAGR of 12.4%, reflecting rising demand across Non-Small Cell Lung Cancer Treatment, Bladder Cancer Treatment, and Head & Neck Cancer Treatment.

  • AstraZeneca, Bristol Myers Squibb, and Merck KGaA are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Durvalumab market and are expected to observe the growth CAGR of 11.2% to 14.9% between 2024 and 2030.

  • Emerging markets including Brazil, South Korea and Saudi Arabia are expected to observe highest growth with CAGR ranging between 8.7% to 13.0%.

  • Transition like Shifting therapeutic focus toward Immunooncology is expected to add $607 million to the Durvalumab market growth by 2030.

  • The Durvalumab market is set to add $5.4 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With Advancements in cancer treatment, and strategic Collaborations and Agreements in Pharmaceutical Industry, Durvalumab market to expand 222% between 2024 and 2034.

durvalumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Durvalumab - Country Share Analysis

Opportunities in the Durvalumab

Partnerships between pharmaceutical companies and research institutions can greatly boost the development of Durvalumab by supporting in depth studies and speeding up the approval process while also enhancing its marketing and distribution efforts to reach an audience, in growing markets seeking advanced cancer treatments.

Growth Opportunities in North America and Asia-Pacific

In North America Durvalumab has a presence in the market due to the growing demand for advanced immunotherapy treatments and the well established healthcare system in the region. It is home to top companies which increases competition for Durvalumab. Newer technologies for cancer treatment and better access to healthcare services are driving factors, in the market. Moreover the increasing prevalence of lung cancer and awareness of immunotherapies are also fueling market growth in this region.
The Asia Pacific region is a market for Durvalumab due to the growing number of cancer patients in countries like China and India. The competition in this region among biopharmaceutical companies is fierce as they pursue aggressive growth strategies to promote the use of Durvalumab. Government initiatives in these countries are also contributing to the expansion of healthcare infrastructure. Improving access to advanced treatment options. The rise in tourism and the increasing elderly population vulnerable to variouss of cancer are major factors driving the demand, for Durvalumab in this region.

Market Dynamics and Supply Chain

01

Driver: Advancements in Cancer Treatment, and Expansion of FDA-approved Indications

The rising prevalence of cancer worldwide has also prompted scientists to explore more flexible treatment options. Durvalumab stands out as an advancement in this area of research being an immunotherapy medication. Its mechanism involves blocking the connection between PD L1 and PD.2 Which helps the system target cancerous cells effectively. The introduction of this form of treatment has also gained significant attention with an increasing need for Durvalumab, in treating lung and bladder cancers. Durvalumabs application is also broadening due to its marked efficacy in treating variouss of cancer. Recently, the FDA has also approved Durvalumab for the treatment of specifics of non-small cell lung cancer and urothelial carcinoma, significantly expanding its application scope.
To speed up the development of drugs and make it easier for patients to get them quickly available in the market several pharmaceutical companies are also teaming up for trials and manufacturing of Durvalumab. These partnerships usually include sharing technology to make improvements, to how Durvalumab is also made and used ultimately impacting the market.
02

Restraint: Regulatory Barriers

Regulatory authorizations play a role in the Durvalumab market sector as the drug has gained FDA approval for specific cancer treatments but still needs clearances from regulatory bodies, in various global regions to expand its reach into new markets smoothly and efficiently—a process that may pose delays and uncertainties impacting the pace of Durvalumabs market entry and growth potential.
03

Opportunity: Pioneering Therapeutic Applications and Technological Innovations

Durvalumab has made an impact on cancer treatment by introducing a highly advanced method that involves blocking the interaction between PD Ll and PD l and CD80 proteins. This innovative approach to therapy presents potential for market expansion. Continuous exploration and innovation, in utilizing Durvalumab for medical purposes could potentially reach previously unexplored groups of patients and help boost its market presence.
Durvalumabs potential for growth is also seen in the advancements of technology like AI and ML in research that can speed up the exploration of new uses, for Durvalumab and drive up its demand even more by possibly creating personalized medicine approaches to enhance the effectiveness of Durvalumab treatment.
04

Challenge: High Treatment Costs

Durvalumabs market growth may be impeded by its high treatment costs. As an innovative immunotherapy drug, Durvalumab is positioned at a premium price point. While it has proven effective in certain situations, the high cost may limit its accessibility to patients in various socio-economic strata, subsequently reducing its overall market demand.

Supply Chain Landscape

1

Raw Material Procurement

Sigma-AldrichThermo Fisher Scientific
2

Drug Synthesis

AstraZenecaEli Lilly and Company
3

Distribution & Logistics

McKesson CorporationAmerisourceBergen Corporation
4

End Users

Oncology clinicshospitals
Durvalumab - Supply Chain

Use Cases of Durvalumab in Non-Small Cell Lung Cancer Treatment & Head & Neck Cancer Treatment

Non-Small Cell Lung Cancer Treatment : Durvalumab, a of Immuno-oncology drug, is majorly utilized in the treatment of non-small cell lung cancer. It uniquely harnesses the body's immune system to target and attack cancer cells, providing a new angle of attack beyond traditional chemotherapies. AstraZeneca, which is widely acknowledged for their substantial work in oncology, appears to have a leading position in this sector, contributing to groundbreaking advancements in non-small cell lung cancer treatment. Their product, Imfinzi , displays strong potential in ensuring a positive patient response and improved survival rate.
Bladder Cancer Treatment : Durvalumab is also becoming indispensable in the management of bladder cancer. As an Immuno-oncology drug, it continues to offer a transformative approach to cancer treatment by stimulating the immune system to more effectively combat cancer cells. AstraZenecas product Imfinzi plays a critical role in the therapeutic arsenal against bladder cancer, with a strong market presence. Its convenient administration and well-measured efficacy set it apart from other treatments, reinforcing the companys strong market positioning.
Head & Neck Cancer Treatment : Yet another application for Durvalumab is in head and neck cancer treatment, where it exhibits notable clinical efficacy and contributes to improved long-term patient outcomes. Its ability to enhance anti-tumor immune responses makes it a valuable option for patients with recurrent or metastatic disease. Ongoing clinical evaluations further highlight its potential for combination therapies, positioning Durvalumab as an integral component in expanding treatment frameworks for complex head and neck oncology cases.

Recent Developments

Durvalumab, one of the burgeoning immunotherapy drugs in the pharmaceutical industry, has experienced remarkable market developments in recent years. As an active participant in non-small cell lung cancer treatment, Durvalumab has carved an enviable niche for itself. Notably, its efficacy in prolonging patient survival rates, thus enhancing patient quality of life, has accelerated its adoption amongst oncologists.

October 2024 : AstraZeneca, a key player in biopharmaceuticals, announced groundbreaking results from the third phase of clinical trials for Durvalumab in combination with chemotherapy, demonstrating significant improvements in patient response rates and survival periods in non-small cell lung cancer treatments
August 2024 : Accelerated approval granted by the US FDA for Durvalumab to be used in first-line treatment for patients suffering from extensive-stage small cell lung cancer, marking a significant milestone for AstraZeneca in cancer therapeutics
June 2024 : New research collaboration forged between leading biopharmaceutical company AstraZeneca and gene-editing pioneer CRISPR Therapeutics to explore the potential of Durvalumab in combination with new gene-editing techniques to enhance cancer immunotherapy

Impact of Industry Transitions on the Durvalumab Market

As a core segment of the Pharmaceutical industry, the Durvalumab market develops in line with broader industry shifts. Over recent years, transitions such as Shifting therapeutic focus toward Immunooncology and Proliferation of Precision Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Durvalumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shifting therapeutic focus toward Immunooncology

The pharmaceuticalindustry'sincreasing focus on immunooncligy represents a shift for Durvalumab. A monoclonal antibody designed to combat variouss of cancer by binding to programmed cell death ligand 13 thereby interrupting its interaction with PD0 and CD80 and enhancing the immune response against cancer cells. This shift towards immunooncligy has significantly expanded the uses and demand for Durvalumab in treating cancers such, as urothelial carcinoma and both small cell and nonsmall cell lung cancer. The change has had an effect on how companies in the pharmaceutical industry plan for growth by increasing their focus on investments and research efforts, in immunoonocology.
02

Proliferation of Precision Medicine

A rise in personalized treatment plans has significantly influenced the use of Durvalumab in recent years. As healthcare systems shift toward targeted therapeutic approaches, Durvalumab is increasingly integrated into biomarker-driven oncology protocols, enhancing treatment alignment with individual patient profiles. This trend supports improved clinical outcomes, optimized dosing strategies, and broader adoption across diverse cancer types. The growing emphasis on precision medicine continues to elevate Durvalumab’s strategic relevance in modern immuno-oncology.